查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2024189

人類基因定序市場：按應用、技術、工作流程、產品和國家/地區分類的策略、趨勢和預測——面向高階主管、顧問的指南以及人工智慧 (AI) 的影響 (2026–2030)

Human Gene Sequencing Markets, Strategies & Trends. Forecasts by Application, by Technology, by Workflow, by Product, and by Country. With Executive and Consultant Guides and Impact of Artificial Intelligence. 2026 to 2030
出版日期: | 出版商: Howe Sound Research | 英文 841 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

市場概況：

人類基因定序是指用於確定DNA中核苷酸精確序列的一系列技術。這些技術能夠識別與疾病風險、治療反應和生物學功能相關的基因變異。自2003年人類基因組計畫完成以來，定序技術的進步顯著降低了成本並提高了處理能力，使基因定序從一項小眾研究活動轉變為臨床診斷、藥物研發和生物醫學研究的核心工具。

隨著精準醫療、腫瘤學、罕見疾病診斷、生殖健康篩檢和藥物基因體學等領域的應用日益廣泛，全球人類基因定序市場正迅速擴張。預計到2025年，市場規模將超過115億美元，到2030年將達214億美元，年均成長率達13.1%。由於能夠同時對數百萬個DNA片段定序，次世代定序（NGS）技術佔了最大的市場佔有率。

人類基因定序技術正日益融入臨床決策流程。基於定序的診斷方法能夠識別與癌症、遺傳疾病和治療反應相關的基因突變。隨著醫療保健系統採用精準醫療方法，基因定序正成為現代臨床實務中不可或缺的一部分。

技術進步

基因定序技術在過去20年中取得了顯著進展。第一代定序方法，例如桑格定序法，曾廣泛用於早期基因組研究，但其處理能力相對較低，且每個樣本的成本較高。

在大多數應用中，次世代定序技術已基本取代了第一代定序方法。 NGS平台能夠同時對數百萬個DNA片段定序，大幅降低了每個鹼基的成本，並有助於進行全面的基因組分析。 NGS技術支援廣泛的應用，包括全基因測序（WGS）、全EXOME定序（WES）、標靶基因panel定序和轉錄組定序。

第三代定序技術，包括單分子定序和長讀長定定序，因其能夠檢測短讀長定序方法難以分析的結構變異和複雜基因組區域，而日益受到關注。長讀長定序技術提高了重複序列和結構重排分析的準確性。

定序工作流程通常包括樣品製備、文庫建構、定序反應和生物資訊分析。自動化技術和基於雲端的生物資訊工具的進步正在提高工作流程效率和數據解讀能力。

主要應用領域

人類基因定序廣泛應用於臨床和研究領域。

腫瘤學是定序技術應用最廣泛的領域之一。定序技術用於識別與癌症發生和發展相關的基因突變。分子譜分析能夠識別具有治療價值的突變，從而指導標靶治療的選擇。

罕見疾病的診斷是另一個重要的應用領域。許多罕見疾病是由遺傳因素引起的，定序技術可以幫助識別導致疾病症狀的致病突變。

非侵入性產前檢測 (NIPT) 利用對母體血液中循環的遊離胎兒 DNA定序，來檢測染色體異常，例如 21 三體症候群。

在藥物基因體學中，遺傳訊息被用來預測患者的藥物反應，並幫助確定合適的劑量。

感染疾病定序有助於監測病毒和細菌病原體，以及監測新出現的變異株。

研究應用包括基因發現、群體基因體學、演化生物學和生物標記鑑定。

市場促進因素

多種因素正在推動人類基因定序市場的成長。

  • 精準醫療方法的日益普及，催生了對基因組資訊的需求，以支持個人化治療決策。
  • 隨著癌症治療方法的不斷發展，利用定序技術來識別治療標靶的應用也日益增加。
  • 大規模人群基因組分析舉措正在催生對高通量定序技術的需求。
  • 技術進步降低了定序成本，提高了定序的可及性。
  • 將基因組檢測納入臨床指南的擴展正在促進其更廣泛的應用。
  • 隨著生物資訊工具的普及，基因組數據的解讀準確性也不斷提高。

市場區隔

人類基因定序市場可以按技術類型、應用、最終用戶和地區進行細分。

從技術角度來看，由於其高通量能力，次世代定序佔了主要佔有率。全基因測序、全EXOME定序和標靶基因panel定序是其主要應用形式。

按應用領域分類，NIPT（非侵入性產前檢測）和腫瘤學佔比最大。

北美是最大的區域市場，這得益於其強大的研究基礎設施和基因組醫學的高普及率。隨著各國政府加大對基因組研究舉措的投入，歐洲和亞太市場也不斷擴張。

競爭格局

人類基因定序市場包括儀器製造商、試劑供應商、定序服務供應商和生物資訊公司。

競爭的驅動力在於定序準確性、通量、成本效益和數據分析能力。

各公司正擴大提供定序設備、耗材和生物資訊軟體結合的整合解決方案。

定序技術提供者與製藥公司之間的策略合作很常見，尤其是在生物標記發現和臨床試驗等應用領域。

資料解讀能力和基因組資料庫取權限正成為重要的競爭優勢。

資本要求、技術專長和監管方面的考慮意味著進入障礙仍然很高。

未來展望

隨著定序技術日益融入醫療系統和調查計畫中，人類基因定序市場預計將繼續擴張。

定序成本的降低預計將促使全基因測序技術的普及。

人工智慧和生物資訊學的進步有望提高基因組數據的解讀能力。

群體基因組分析工作可能促使定序技術在預防醫學領域得到更廣泛的應用。

將基因組數據整合到電子健康記錄中，有可能為個人化醫療方法提供支援。

新興的長讀長定序技術有可能提高檢測結構變異和複雜基因組特徵的準確性。

總體而言，人類基因定序是一項基礎性技術，為精準醫療、生物醫學研究和藥物研發提供支援。持續的技術創新和不斷擴展的臨床應用預計將推動市場長期成長。

目錄

第1章 市集指南

  • 人類基因定序市場—戰略情勢分析
    • 精準醫療的策略意義
    • 降低成本和經濟壓力
    • 技術創新與平台競爭
    • 數據分析和生物資訊學面臨的挑戰
    • 監管和倫理方面的考量
    • 報銷和臨床啟動的障礙
    • 競爭格局與產業結構
    • 擴大臨床應用範圍
    • 展望與戰略意義
  • 企業主管、行銷負責人、銷售負責人和業務拓展負責人。
  • 管理顧問和投資顧問指南
  • 人工智慧對基因序列測定市場的影響

第2章：引言與市場定義

  • 本報告中基因序列測定的定義
    • 基因序列測定
    • 遺傳
    • 非侵入性產前檢測
    • 腫瘤學
    • 心理學
    • WGES
    • 藥理基因體學
    • 直接向消費者銷售
    • 研究
    • 其他
  • 基因組革命
  • 市場定義
    • 營收市場規模
  • 調查方法
  • 展望：醫療保健和體外診斷產業
  • 染色體、基因、表觀遺傳學

第3章：序列器安裝狀態列表 - 安裝位置和聯絡資訊

第4章 市場概覽

  • 參與企業充滿活力的市場
    • 學術研究辦公室
    • 診斷測試開發人員
    • 測量儀器供應商
    • 化學品/試劑供應商
    • 病理檢測用品供應商
    • 獨立臨床實驗室
    • 國家/地區公共研究機構
    • 醫院檢查室
    • 醫師診所檢查室（POLS）
    • 審計機構
    • 認證機構
  • 人類基因定序—市場、案例研究與洞察
  • 產業結構

第5章 市場趨勢

  • 成長促進因素
  • 成長阻礙因素
  • 序列分析儀

第6章：人類基因定序的最新趨勢

第7章：主要企業概況

  • 10x Genomics, Inc.
  • 23andME Inc.
  • Abbott Laboratories
  • AccuraGen Inc.
  • Adaptive Biotechnologies
  • Admera Health, LLC
  • Advanced Biological Laboratories
  • Agilent
  • Akonni Biosystems
  • Amoy Diagnostics Co., Ltd.
  • Ancestry.com LLC
  • Anchor Dx
  • Arrayit Corporation
  • ARUP Laboratories
  • Astrid Bio
  • Azenta
  • BaseClear
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter Diagnostics（Danaher）
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • BioBam
  • Biocept, Inc.
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • Biolidics Ltd
  • bioMerieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne
  • Burning Rock
  • C2i Genomics
  • Cantata Bio
  • CareDx
  • Caris Molecular Diagnostics
  • Celemics
  • CellMax Life
  • Centogene
  • Cepheid（Danaher）
  • Circulogene
  • Clearbridge Biomedics
  • Clinical Genomics
  • Color Genomics
  • Complete Genomics（MGI Tech）
  • CosmosID
  • Dante Labs
  • Datar Cancer Genetics Limited
  • Diasorin SpA
  • Easy DNA
  • Element Biosciences
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Excellerate Bioscience
  • Fabric Genomics
  • Freenome
  • FUJIFILM Wako Diagnostics
  • Fujirebio
  • Fulgent Genetics
  • GE Global Research
  • Gene by Gene, Ltd.
  • Genedrive
  • GeneDx Holdings
  • GeneFirst Ltd.
  • GeneFluidics
  • Genetron Holdings
  • Genewiz
  • Genomics England
  • Genomics Personalized Health（GPH）
  • GenomOncology
  • Genzyme Corporation
  • Grifols
  • Guardant Health
  • Guardiome
  • Helix
  • Hologic
  • HTG Molecular Diagnostics
  • Human Longevity, Inc.
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Invitae Corporation
  • Invivoscribe
  • Karius
  • Letsgetchecked
  • Lucence Health
  • Lunglife AI Inc
  • Macrogen
  • MDNA Life SCIENCES, Inc.
  • MDx Health
  • Medgenome
  • Meridian Bioscience
  • Mesa Laboratories, Inc.
  • Metabiomics Corp
  • miR Scientific
  • NantHealth, Inc.
  • Natera
  • Nebula Genomics
  • NeoGenomics
  • New England Biolabs, Inc.
  • NGeneBio
  • Norgen Biotek Corp.
  • Novogene
  • Omega Bioservices
  • Oncocyte
  • OncoDNA
  • OpGen
  • Origene Technologies
  • Oxford Nanopore Technologies
  • Pacific Biosciences
  • Panagene
  • PathoQuest SA
  • Personalis
  • PGDx（Labcorp）
  • Precipio
  • PrecisionMed
  • Predictive Oncology
  • Promega
  • Qiagen
  • QuantuMDx
  • Regeneron Pharmaceuticals
  • Revvity
  • Roche Diagnostics
  • Roswell Biotechnologies
  • Seegene
  • SeLux Diagnostics
  • Sequencing.com
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc.
  • Singular Genomics
  • SkylineDx
  • Standard BioTools
  • Sysmex
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific
  • Ultima Genomics
  • Unchained Labs
  • Variantyx
  • Vela Diagnostics
  • VolitionRX
  • Zymo Research Corp

第8章：全球人類基因定序市場

  • 全球市場各國概覽
  • 全球市場概覽（按應用領域分類）
  • 全球市場概覽（依技術分類）
  • 全球市場概覽（依工作流程分類）
  • 全球市場概覽（按產品類別分類）

第9章 按應用分類的市場規模

  • 遺傳基因定序市場
  • NIPT基因定序市場
  • 腫瘤市場
  • 心理市場
  • WGES基因定序市場
  • 藥物基因組學市場
  • DTC基因定序市場
  • 研究基因定序市場
  • 其他

第10章 按技術分類的市場規模

  • 桑格定序市場
  • NGS/2G市場
  • 3G/長市場
  • 其他

第11章 依工作流程分類的市場規模

  • 定序市場
  • 樣品製備市場
  • 分析市場

第12章 按產品分類的市場規模

  • 測量儀器市場
  • 消費品市場
  • 軟體與服務市場

第13章：人類基因定序的未來

第14章附錄

表格一覽

圖表清單

簡介目錄
Product Code: GENSEQ 426

Market Overview:

Human gene sequencing refers to a group of technologies used to determine the precise order of nucleotides within DNA. These technologies enable identification of genetic variations associated with disease risk, treatment response, and biological function. Since completion of the Human Genome Project in 2003, advances in sequencing technologies have dramatically reduced cost and improved throughput, transforming gene sequencing from a specialized research activity into a core tool for clinical diagnostics, pharmaceutical development, and biomedical research.

The global human gene sequencing market has expanded rapidly as applications in precision medicine, oncology, rare disease diagnostics, reproductive health screening, and pharmacogenomics have grown. The market is over USD 11.5 Billion in 2025 and growing to 21.4 Billion by 2030. This represents a growth rate of 13.1%. Next-generation sequencing (NGS) represents the largest technology segments due to its ability to sequence millions of DNA fragments simultaneously.

Human gene sequencing technologies are increasingly integrated into clinical decision-making processes. Sequencing-based diagnostics enable identification of genetic mutations associated with cancer, inherited diseases, and treatment response. As healthcare systems adopt precision medicine approaches, gene sequencing is becoming an essential component of modern clinical practice.

Technology Evolution

Gene sequencing technologies have evolved significantly over the past two decades. First-generation sequencing methods, such as Sanger sequencing, were widely used for early genomic research but were limited by relatively low throughput and high cost per sample.

Next-generation sequencing technologies have largely replaced first-generation methods for most applications. NGS platforms allow simultaneous sequencing of millions of DNA fragments, enabling comprehensive genomic analysis at significantly lower cost per base. NGS technologies support a range of applications including whole genome sequencing (WGS), whole exome sequencing (WES), targeted gene panels, and transcriptome sequencing.

Third-generation sequencing technologies, including single-molecule and long-read sequencing methods, are gaining increasing attention due to their ability to detect structural variants and complex genomic regions that may be difficult to analyze using short-read methods. Long-read sequencing technologies provide improved characterization of repetitive sequences and structural rearrangements.

Sequencing workflows typically involve sample preparation, library construction, sequencing reactions, and bioinformatics analysis. Advances in automation and cloud-based bioinformatics tools have improved workflow efficiency and data interpretation capabilities.

Key Applications

Human gene sequencing is used across a wide range of clinical and research applications.

Oncology represents one of the largest application areas. Sequencing technologies are used to identify genetic mutations associated with cancer development and progression. Molecular profiling enables identification of actionable mutations that can guide targeted therapy selection.

Rare disease diagnostics represent another important application area. Many rare diseases have genetic origins, and sequencing technologies can help identify pathogenic variants responsible for disease symptoms.

Non-invasive prenatal testing (NIPT) uses sequencing of cell-free fetal DNA circulating in maternal blood to detect chromosomal abnormalities such as trisomy 21.

Pharmacogenomics uses genetic information to predict patient response to drugs and guide dosing decisions.

Infectious disease sequencing supports surveillance of viral and bacterial pathogens and monitoring of emerging variants.

Research applications include gene discovery, population genomics, evolutionary biology, and biomarker identification.

Market Drivers

Several factors are driving growth in the human gene sequencing market.

  • Increasing adoption of precision medicine approaches is creating demand for genomic information that supports personalized treatment decisions.
  • Growth in oncology drug development is increasing use of sequencing technologies to identify therapeutic targets.
  • Large population genomics initiatives are generating demand for high-throughput sequencing technologies.
  • Technological advances are reducing sequencing costs and improving accessibility.
  • Expansion of clinical guidelines incorporating genomic testing is supporting broader adoption.
  • Increasing availability of bioinformatics tools is improving interpretation of genomic data.

Market Segmentation

The human gene sequencing market can be segmented by technology type, application, end user, and geographic region.

By technology, next-generation sequencing represents the dominant segment due to high throughput capabilities. Whole genome sequencing, whole exome sequencing, and targeted gene panels represent important application formats.

By application, NIPT and Oncology represents the largest segments.

North America represents the largest geographic market due to strong research infrastructure and high adoption of genomic medicine. Europe and Asia-Pacific markets are also expanding as governments invest in genomic research initiatives.

Competitive Landscape

The human gene sequencing market includes instrument manufacturers, reagent suppliers, sequencing service providers, and bioinformatics companies.

Competition is driven by sequencing accuracy, throughput, cost efficiency, and data analysis capabilities.

Companies are increasingly offering integrated solutions combining sequencing instruments, consumables, and bioinformatics software.

Strategic partnerships between sequencing technology providers and pharmaceutical companies are common, particularly in biomarker discovery and clinical trial applications.

Data interpretation capabilities and access to genomic databases are becoming important competitive differentiators.

Barriers to entry remain significant due to capital requirements, technical expertise, and regulatory considerations.

Future Outlook

The human gene sequencing market is expected to continue expanding as sequencing technologies become more integrated into healthcare systems and research programs.

Declining sequencing costs are expected to increase adoption of whole genome sequencing.

Advances in artificial intelligence and bioinformatics are expected to improve interpretation of genomic data.

Population genomics initiatives may increase use of sequencing technologies in preventive medicine.

Integration of genomic data into electronic health records may support personalized treatment approaches.

Emerging long-read sequencing technologies may improve detection of structural variants and complex genomic features.

Overall, human gene sequencing represents a foundational technology supporting precision medicine, biomedical research, and drug development. Continued technological innovation and expanding clinical applications are expected to drive long-term market growth.

Table of Contents

1 Market Guides

  • 1.1 Human Gene Sequencing Markets - Strategic Situation Analysis
    • 1.1.1 Strategic Importance in Precision Medicine
    • 1.1.2 Cost Reduction and Economic Pressures
    • 1.1.3 Technology Innovation and Platform Competition
    • 1.1.4 Data Analysis and Bioinformatics Challenges
    • 1.1.5 Regulatory and Ethical Considerations
    • 1.1.6 Reimbursement and Clinical Adoption Barriers
    • 1.1.7 Competitive Landscape and Industry Structure
    • 1.1.8 Expansion of Clinical Applications
    • 1.1.9 Outlook and Strategic Implications
  • 1.2 Guide for Executives, Marketing, Sales and Business Development Staff
  • 1.3 Guide for Management Consultants and Investment Advisors
  • 1.4 Impact of Artificial Intelligence on Gene Sequencing Market

2 Introduction and Market Definition

  • 2.1 Gene Sequencing Definition In This Report
    • 2.1.1 Gene Sequencing
    • 2.1.2 Hereditary
    • 2.1.3 Non Invasive Prenatal Testing
    • 2.1.4 Oncology
    • 2.1.5 Psychology
    • 2.1.6 WGES
    • 2.1.7 Pharmacogenomic
    • 2.1.8 Direct to Consumer
    • 2.1.9 Research
    • 2.1.10 Other
  • 2.2 The Genomics Revolution
  • 2.3 Market Definition
    • 2.3.1 Revenue Market Size
  • 2.4 Methodology
    • 2.4.1 Methodology
    • 2.4.2 Sources
    • 2.4.3 Authors
  • 2.5 Perspective: Healthcare and the IVD Industry
    • 2.5.1 Global Healthcare Spending
    • 2.5.2 Spending on Diagnostics
    • 2.5.3 Important Role of Insurance for Diagnostics
  • 2.6 Chromosomes, Genes and Epigenetics
    • 2.6.1 Chromosomes
    • 2.6.2 Genes
    • 2.6.3 Epigenetics
    • 2.6.4 Genetic Testing vs. Gene Sequencing
    • 2.6.5 Cost and Pricing Practice

3 Global Listing of Sequencer Installed Base - Location & Contacts

  • 3.1 Notes to Installed Base Listing
  • 3.2 Illumina Installed Base

4 Market Overview

  • 4.1 Players in a Dynamic Market
    • 4.1.1 Academic Research Lab
    • 4.1.2 Diagnostic Test Developer
    • 4.1.3 Instrumentation Supplier
    • 4.1.4 Chemical/Reagent Supplier
    • 4.1.5 Pathology Supplier
    • 4.1.6 Independent Clinical Laboratory
    • 4.1.7 Public National/regional Laboratory
    • 4.1.8 Hospital Laboratory
    • 4.1.9 Physicians Office Lab (POLS)
    • 4.1.10 Audit Body
    • 4.1.11 Certification Body
  • 4.2 Human Gene Sequencing - Markets, Examples and Discussion
    • 4.2.1 Inherited Disease - Not what it used to be
      • 4.2.1.1 Clinical and Research Lines Blur
      • 4.2.1.2 Genetic Counselling - Not so simple anymore
      • 4.2.1.3 The Genetic Blizzard - Issues of Access and Payment
    • 4.2.2 Newborn Screening - The Standard of Care
      • 4.2.2.1 Newborn Screening - Do Parents Want to Know?
    • 4.2.3 NIPT - We've Only Just Begun
      • 4.2.3.1 NIPT, IVF and the Fertility Practice - PGS, PGD, CCS
      • 4.2.3.2 NIPT in the Future - Beyond Inherited Disease
    • 4.2.4 Oncology - Understanding Two Worlds
      • 4.2.4.1 The Tumor - A Sequence of Sequencing
      • 4.2.4.2 The Tumor - Biopsy and Liquid Biopsy
      • 4.2.4.3 The Human Genome - Predisposition and Prognosis
    • 4.2.5 Pharmacogenomics
      • 4.2.5.1 Sequencing Not the Only Player
      • 4.2.5.2 New Roles for Old Drugs - A Research Bonanza?
    • 4.2.6 Direct To Consumer - More Than Meets the Eye
      • 4.2.6.1 DTC - How Many Segments?
  • 4.3 Industry Structure
    • 4.3.1 Hospital's Testing Share
    • 4.3.2 The Rise of the Sequencing Lab
    • 4.3.3 Sequencing as a Commodity
    • 4.3.4 Informatics
    • 4.3.5 Instrument Manufacturer Role
    • 4.3.6 Healthcare Industry Impacts - Still Struggling
    • 4.3.7 Can the Healthcare Industry Adapt?
    • 4.3.8 Genetic Counselling as an Industry
    • 4.3.9 Sequencing Adoption and Cannibalization

5 Market Trends

  • 5.1 Factors Driving Growth
    • 5.1.1 New Diagnoses
    • 5.1.2 Wellness and Prevention
    • 5.1.3 Fertility Technology
    • 5.1.4 Cancer - Screening, Management and Monitoring
  • 5.2 Factors Limiting Growth
    • 5.2.1 Increased Competition Lowers Price
    • 5.2.2 Lower Costs
    • 5.2.3 Healthcare Cost Concerns Curtail Growth
    • 5.2.4 Wellness has a downside
  • 5.3 Sequencing Instrumentation
    • 5.3.1 Instrumentation Tenacity
    • 5.3.2 Declining Cost of Instruments Changes Industry Structure
    • 5.3.3 Long Reads - Further Segmentation
    • 5.3.4 Linked Reads
    • 5.3.5 New Sequencing Technologies

6 Human Gene Sequencing Recent Developments

  • 6.1 Recent Developments - Importance and How to Use This Section
    • 6.1.1 Importance of These Developments
    • 6.1.2 How to Use This Section
  • 6.2 Adaptive Biotechnologies MRD Testing Grows
  • 6.3 GeneDx to Acquire Fabric Genomics
  • 6.4 Inclusive Newborn Sequencing Shows Potential
  • 6.5 Delve Bio: Delve Detect
  • 6.6 Caris CDx Assay Approval
  • 6.7 Ambry Genetics: ExomeReveal
  • 6.8 WGS Improves Pediatric Cancer Care
  • 6.9 Cancer genomes identify candidate driver genes
  • 6.10 Genetic Dx a game changer
  • 6.11 Nonacus Galeas Tumor
  • 6.12 Lucence LiquidHallmark Assay Gets Coverage
  • 6.13 Garvan Institute Gets Gramt to Develop Genomics Tests
  • 6.14 Arima Genomics, Protean BioDiagnostics Launch Joint Venture
  • 6.15 Geneseeq Nabs CE Marks for Cancer Test Kits
  • 6.16 Viome Life Sciences Announces Gut Intelligence Test
  • 6.17 Quest Diagnostics Announces Genetic Insights
  • 6.18 Exact Sciences Releases Next-Gen Cologuard
  • 6.19 BGI Genomics Forges Partnerships in Latin America
  • 6.20 4bases Bets on NGS Diagnostics
  • 6.21 Guardant Health Submits Colorectal Cancer Screening Test
  • 6.22 Universal DX Eyeing Approval for Colorectal Cancer Screening Test
  • 6.23 Natera Files Suit Against NeoGenomics
  • 6.24 Genomics England to Sequence 100K Newborns
  • 6.25 Novigenix Raises $14M for NGS based Liquid Biopsy
  • 6.26 LetsGetChecked Launching New PGx Service
  • 6.27 Qiagen, Neuron23 Partner for NGS Diagnostic
  • 6.28 Harbinger Health Technology Focused On Oncogenesis
  • 6.29 Delfi Diagnostics to Develop Early Detection Test
  • 6.30 Dante Labs to Introduce WGS to Italian Healthcare System
  • 6.31 Invitae Neurodevelopmental Disorders Testing Service
  • 6.32 Thermo Fisher Obtains CE Mark for Ion Torrent Genexus
  • 6.33 Myriad Genetics Launches Suite of Cancer Tests
  • 6.34 Oncocyte and Thermo Fisher Strike Partnership Deal
  • 6.35 Illumina Partners With Precision Medicine to Assess Liquid Biopsy
  • 6.36 Sysmex Inostics Develops Ultra-Sensitive Liquid Biopsy
  • 6.37 Twist Bioscience, Centogene Partner on NGS-Based Rare Disease Testing
  • 6.38 Strata Oncology Trial Supports NGS Assay
  • 6.39 NYU Gets FDA Clearance for Sequencing Test
  • 6.40 NeoGenomics to Acquire Inivata
  • 6.41 OncoDNA, Institut Curie Partner on Liquid Biopsy Research
  • 6.42 Cancer Heritability Gene Set Expanded
  • 6.43 Whole-Genome Sequencing Could Replace Cytogenetics
  • 6.44 Twist Bioscience, Berry Genomics Partner on Targeted NGS Assays
  • 6.45 Ancestry Shutters Health Offering
  • 6.46 Genetron Health Targeting Early Cancer Detection
  • 6.47 Pan-European Initiative to Build Tools for Sharing Genomic Data
  • 6.48 UK Government Unveils New Genomic Healthcare Strategy
  • 6.49 Foundation Medicine Liquid Biopsy Gets FDA Approval
  • 6.50 American Heart Association Develops Genetic Testing Guidelines
  • 6.51 Yourgene Health Gets CE Mark for Iona NIPT Test
  • 6.52 NorthShore Looks to Expand Genomics Integration Into Primary Care
  • 6.53 Germline Results From Tumor Sequencing Guides Precision Therapy
  • 6.54 FDA Clears Cancer Genomic Profiling From Personal Genome Diagnostics
  • 6.55 BillionToOne Closes $15M Series A Follow-on Round
  • 6.56 Clinics to Integrate Genomics Into Primary Care

7 Profiles of Key Companies

  • 7.1 10x Genomics, Inc.
  • 7.2 23andME Inc.
  • 7.3 Abbott Laboratories
  • 7.4 AccuraGen Inc.
  • 7.5 Adaptive Biotechnologies
  • 7.6 Admera Health, LLC
  • 7.7 Advanced Biological Laboratories
  • 7.8 Agilent
  • 7.9 Akonni Biosystems
  • 7.10 Amoy Diagnostics Co., Ltd.
  • 7.11 Ancestry.com LLC
  • 7.12 Anchor Dx
  • 7.13 Arrayit Corporation
  • 7.14 ARUP Laboratories
  • 7.15 Astrid Bio
  • 7.16 Azenta
  • 7.17 BaseClear
  • 7.18 Baylor Miraca Genetics Laboratories
  • 7.19 Beckman Coulter Diagnostics (Danaher)
  • 7.20 Becton, Dickinson and Company
  • 7.21 BGI Genomics Co. Ltd
  • 7.22 Bioarray Genetics
  • 7.23 BioBam
  • 7.24 Biocept, Inc.
  • 7.25 Biodesix Inc.
  • 7.26 BioFluidica
  • 7.27 BioGenex
  • 7.28 Biolidics Ltd
  • 7.29 bioMerieux Diagnostics
  • 7.30 Bioneer Corporation
  • 7.31 Bio-Rad Laboratories, Inc.
  • 7.32 Bio-Techne
  • 7.33 Burning Rock
  • 7.34 C2i Genomics
  • 7.35 Cantata Bio
  • 7.36 CareDx
  • 7.37 Caris Molecular Diagnostics
  • 7.38 Celemics
  • 7.39 CellMax Life
  • 7.40 Centogene
  • 7.41 Cepheid (Danaher)
  • 7.42 Circulogene
  • 7.43 Clearbridge Biomedics
  • 7.44 Clinical Genomics
  • 7.45 Color Genomics
  • 7.46 Complete Genomics (MGI Tech)
  • 7.47 CosmosID
  • 7.48 Dante Labs
  • 7.49 Datar Cancer Genetics Limited
  • 7.50 Diasorin S.p.A.
  • 7.51 Easy DNA
  • 7.52 Element Biosciences
  • 7.53 Epic Sciences
  • 7.54 Epigenomics AG
  • 7.55 Eurofins Scientific
  • 7.56 Excellerate Bioscience
  • 7.57 Fabric Genomics
  • 7.58 Freenome
  • 7.59 FUJIFILM Wako Diagnostics
  • 7.60 Fujirebio
  • 7.61 Fulgent Genetics
  • 7.62 GE Global Research
  • 7.63 Gene by Gene, Ltd.
  • 7.64 Genedrive
  • 7.65 GeneDx Holdings
  • 7.66 GeneFirst Ltd.
  • 7.67 GeneFluidics
  • 7.68 Genetron Holdings
  • 7.69 Genewiz
  • 7.70 Genomics England
  • 7.71 Genomics Personalized Health (GPH)
  • 7.72 GenomOncology
  • 7.73 Genzyme Corporation
  • 7.74 Grifols
  • 7.75 Guardant Health
  • 7.76 Guardiome
  • 7.77 Helix
  • 7.78 Hologic
  • 7.79 HTG Molecular Diagnostics
  • 7.80 Human Longevity, Inc.
  • 7.81 iCellate
  • 7.82 Illumina
  • 7.83 Incell Dx
  • 7.84 Inivata
  • 7.85 Invitae Corporation
  • 7.86 Invivoscribe
  • 7.87 Karius
  • 7.88 Letsgetchecked
  • 7.89 Lucence Health
  • 7.90 Lunglife AI Inc
  • 7.91 Macrogen
  • 7.92 MDNA Life SCIENCES, Inc.
  • 7.93 MDx Health
  • 7.94 Medgenome
  • 7.95 Meridian Bioscience
  • 7.96 Mesa Laboratories, Inc.
  • 7.97 Metabiomics Corp
  • 7.98 miR Scientific
  • 7.99 NantHealth, Inc.
  • 7.100 Natera
  • 7.101 Nebula Genomics
  • 7.102 NeoGenomics
  • 7.103 New England Biolabs, Inc.
  • 7.104 NGeneBio
  • 7.105 Norgen Biotek Corp.
  • 7.106 Novogene
  • 7.107 Omega Bioservices
  • 7.108 Oncocyte
  • 7.109 OncoDNA
  • 7.110 OpGen
  • 7.111 Origene Technologies
  • 7.112 Oxford Nanopore Technologies
  • 7.113 Pacific Biosciences
  • 7.114 Panagene
  • 7.115 PathoQuest S.A.
  • 7.116 Personalis
  • 7.117 PGDx (Labcorp)
  • 7.118 Precipio
  • 7.119 PrecisionMed
  • 7.120 Predictive Oncology
  • 7.121 Promega
  • 7.122 Qiagen
  • 7.123 QuantuMDx
  • 7.124 Regeneron Pharmaceuticals
  • 7.125 Revvity
  • 7.126 Roche Diagnostics
  • 7.127 Roswell Biotechnologies
  • 7.128 Seegene
  • 7.129 SeLux Diagnostics
  • 7.130 Sequencing.com
  • 7.131 Siemens Healthineers
  • 7.132 simfo GmbH
  • 7.133 Singlera Genomics Inc.
  • 7.134 Singular Genomics
  • 7.135 SkylineDx
  • 7.136 Standard BioTools
  • 7.137 Sysmex
  • 7.138 Sysmex Inostics
  • 7.139 Tempus Labs, Inc.
  • 7.140 Thermo Fisher Scientific
  • 7.141 Ultima Genomics
  • 7.142 Unchained Labs
  • 7.143 Variantyx
  • 7.144 Vela Diagnostics
  • 7.145 VolitionRX
  • 7.146 Zymo Research Corp

8 The Global Market for Human Genome Sequencing

  • 8.1 Global Market Overview by Country
    • 8.1.1 Table - Global Market by Country
    • 8.1.2 Chart - Global Market by Country
  • 8.2 Global Market by Application - Overview
    • 8.2.1 Table - Global Market by Application
    • 8.2.2 Chart - Global Market by Application - Base/Final Year Comparison
    • 8.2.3 Chart - Global Market by Application - Base Year
    • 8.2.4 Chart - Global Market by Application - Final Year
    • 8.2.5 Chart - Global Market by Application - Share by Year
    • 8.2.6 Chart - Global Market by Application - Segment Growth
  • 8.3 Global Market by Technology - Overview
    • 8.3.1 Table - Global Market by Technology
    • 8.3.2 Chart - Global Market by Technology - Base/Final Year Comparison
    • 8.3.3 Chart - Global Market by Technology - Base Year
    • 8.3.4 Chart - Global Market by Technology - Final Year
    • 8.3.5 Chart - Global Market by Technology - Share by Year
    • 8.3.6 Chart - Global Market by Technology - Segment Growth
  • 8.4 Global Market by Workflow - Overview
    • 8.4.1 Table - Global Market by Workflow
    • 8.4.2 Chart - Global Market by Workflow - Base/Final Year Comparison
    • 8.4.3 Chart - Global Market by Workflow - Base Year
    • 8.4.4 Chart - Global Market by Workflow - Final Year
    • 8.4.5 Chart - Global Market by Workflow - Share by Year
    • 8.4.6 Chart - Global Market by Workflow - Segment Growth
  • 8.5 Global Market by Product - Overview
    • 8.5.1 Table - Global Market by Product
    • 8.5.2 Chart - Global Market by Product - Base/Final Year Comparison
    • 8.5.3 Chart - Global Market by Product - Base Year
    • 8.5.4 Chart - Global Market by Product - Final Year
    • 8.5.5 Chart - Global Market by Product - Share by Year
    • 8.5.6 Chart - Global Market by Product - Segment Growth

9 Market Sizes by Application

  • 9.1 Hereditary Gene Sequencing Market
    • 9.1.1 Table - Hereditary by Country
    • 9.1.2 Chart - Hereditary Segment Growth
  • 9.2 NIPT Gene Sequencing Market
    • 9.2.1 Table NIPT by Country
    • 9.2.2 Chart - NIPT Growth
  • 9.3 Oncology Market
    • 9.3.1 Table - Oncology by Country
    • 9.3.2 Chart - Oncology Growth
  • 9.4 Psychology Market
    • 9.4.1 Table - Psychology by Country
    • 9.4.2 Chart - Psychology Growth
  • 9.5 WGES Gene Sequencing Market
    • 9.5.1 Table - WGES by Country
    • 9.5.2 Chart - WGES growth
  • 9.6 Pharmacogenomics Market
    • 9.6.1 Table Pharmacogenomics by Country
    • 9.6.2 Chart - Pharmacogenomics Growth
  • 9.7 DTC Gene Sequencing Market
    • 9.7.1 Table - DTC by Country
    • 9.7.2 Chart - DTC Growth
  • 9.8 Research Gene Sequencing Market
    • 9.8.1 Table - Research by Country
    • 9.8.2 Chart - Research Growth
  • 9.9 Other Application Market
    • 9.9.1 Table - Other Application by Country
    • 9.9.2 Chart - Other Application growth

10 Market Sizes by Technology

  • 10.1 Sanger Sequencing Market
    • 10.1.1 Table - Sanger by Country
    • 10.1.2 Chart - Sanger Segment Growth
  • 10.2 NGS/2G Market
    • 10.2.1 Table NGS/2G by Country
    • 10.2.2 Chart - NGS/2G Growth
  • 10.3 3G/Long Market
    • 10.3.1 Table - 3G/Long by Country
    • 10.3.2 Chart - 3G/Long Growth
  • 10.4 Other Technology Market
    • 10.4.1 Table - Other Technology by Country
    • 10.4.2 Chart - Other Technology Growth

11 Market Sizes by Workflow

  • 11.1 Sequencing Market
    • 11.1.1 Table - Sequencing by Country
    • 11.1.2 Chart - Sequencing Segment Growth
  • 11.2 Sample Prep Market
    • 11.2.1 Table Sample Prep by Country
    • 11.2.2 Chart - Sample Prep Growth
  • 11.3 Analysis Market
    • 11.3.1 Table - Analysis by Country
    • 11.3.2 Chart - Analysis Growth

12 Market Sizes by Product

  • 12.1 Instruments Market
    • 12.1.1 Table - Instruments by Country
    • 12.1.2 Chart - Instruments Segment Growth
  • 12.2 Consumables Market
    • 12.2.1 Table Consumables by Country
    • 12.2.2 Chart - Consumables Growth
  • 12.3 Software & Services Market
    • 12.3.1 Table - Software & Services by Country
    • 12.3.2 Chart - Software & Services Growth

13 Vision of the Future of Human Gene Sequencing

14 Appendices

  • 14.1 Growth of Approved IVD Test Menu
  • 14.2 Growth of Approved Average IVD Test Fee
  • 14.3 The Most Used IVD Assays
  • 14.4 The Highest Grossing Assays
  • 14.5 Laboratory Fees Schedule
  • 14.6 The Whole Genome Sequence of SARS-CoV-2

Table of Tables

  • Table 1 The Base Pairs
  • Table 2 Most Common Traditional Genetic Disorders
  • Table 3 The Base Pairs
  • Table 4 List of GLOBAL SEQUENCING LOCATIONS
  • Table 5 Market Players by Type
  • Table 6 The Different Markets for Human Gene Sequencing
  • Table 7 DTC Sub Segments
  • Table 8 The Factors Driving Growth
  • Table 9 Factors Limiting Growth
  • Table 10 Six New Sequencing Technologies
  • Table 11 - Global Market by Region
  • Table 12 Global Market by Application
  • Table 13 Global Market by Technology
  • Table 14 Global Market by Workflow
  • Table 15 Global Market by Product
  • Table 16 Hereditary Segment by Country
  • Table 17 NIPT Segment by Country
  • Table 18 Oncology Segment by Country
  • Table 19 Psychology Segment by Country
  • Table 20 WGES Segment by Country
  • Table 21 Pharmacogenomics Segment by Country
  • Table 22 DTC Segment by Country
  • Table 23 Research Segment by Country
  • Table 24 Other Application Segment by Country
  • Table 25 Sanger Segment by Country
  • Table 26 NGS/2G Segment by Country
  • Table 27 3G/Long Segment by Country
  • Table 28 Other Technology by Country
  • Table 29 Sequencing Segment by Country
  • Table 30 Sample Prep Segment by Country
  • Table 31 Analysis Segment by Country
  • Table 32 Instruments Segment by Country
  • Table 33 Consumables Segment by Country
  • Table 34 Software & Services Segment by Country
  • Table 35 The Most Common Assays
  • Table 36 Largest Revenue Assays
  • Table 37 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1 Global Healthcare Spending
  • Figure 2 The Lab Test Pie
  • Figure 3 DNA Strands and Chromosomes
  • Figure 4 Karyogram of Human Chromosomes
  • Figure 5 Size of Various Genomes
  • Figure 6 Global Illumina Installed Base Map
  • Figure 7 The Road to Diagnostics
  • Figure 8 TruSight Germline Panel
  • Figure 9 Historical Cost of Gene Sequencing
  • Figure 10 - Cost To Sequence a Human Genome
  • Figure 11 Base Year Country Market Share Chart
  • Figure 12 Global Market by Application - Base vs. Final Year
  • Figure 13 Global Market by Application Base Year
  • Figure 14 Global Market by Application Final Year
  • Figure 15 Application Type Share by Year
  • Figure 16 by Application Segment Growth
  • Figure 17 Global Market by Technology - Base vs. Final Year
  • Figure 18 Global Market by Technology Base Year
  • Figure 19 Global Market by Technology Final Year
  • Figure 20 Technology Type Share by Year
  • Figure 21 by Technology Segment Growth
  • Figure 22 Global Market by Workflow - Base vs. Final Year
  • Figure 23 Global Market by Workflow Base Year
  • Figure 24 Global Market by Workflow Final Year
  • Figure 25 Workflow Type Share by Year
  • Figure 26 by Workflow Segment Growth
  • Figure 27 Global Market by Product - Base vs. Final Year
  • Figure 28 Global Market by Product Base Year
  • Figure 29 Global Market by Product Final Year
  • Figure 30 Product Type Share by Year
  • Figure 31 by Product Segment Growth
  • Figure 32 Hereditary vs. Total Market Growth
  • Figure 33 NIPT vs. Total Market Growth
  • Figure 34 Oncology vs. Total Market Growth
  • Figure 35 Psychology vs. Total Market Growth
  • Figure 36 WGES vs. Total Market Growth
  • Figure 37 Pharmacogenomics vs. Total Market Growth
  • Figure 38 DTC vs. Total Market Growth
  • Figure 39 Research vs. Total Market Growth
  • Figure 40 Other Application vs. Total Market Growth
  • Figure 41 Sanger vs. Total Market Growth
  • Figure 42 NGS/2G vs. Total Market Growth
  • Figure 43 3G/Long vs. Total Market Growth
  • Figure 44 Other Technology vs. Total Market Growth
  • Figure 45 Sequencing vs. Total Market Growth
  • Figure 46 Sample Prep vs. Total Market Growth
  • Figure 47 Analysis vs. Total Market Growth
  • Figure 48 Instruments vs. Total Market Growth
  • Figure 49 Consumables vs. Total Market Growth
  • Figure 50 Software & Services vs. Total Market Growth
  • Figure 51 IVD Test Menu Growth
  • Figure 52 IVD Test Average Fees - A Ten Year View